IVIG Administration for Guillain-Barré Syndrome
For GBS patients, administer IVIG at 0.4 g/kg/day intravenously for 5 consecutive days, for a total cumulative dose of 2 g/kg. 1, 2, 3
Dosing Protocol
The standard regimen is straightforward:
- Daily dose: 0.4 g/kg body weight
- Duration: 5 consecutive days
- Total dose: 2 g/kg cumulative
This dosing applies to all grades of GBS severity, though the urgency and monitoring intensity differ 1, 2.
Infusion Rate and Administration
Start the infusion at 0.01 mL/kg/min (0.5 mg/kg/min) and gradually increase to a maximum of 0.10 mL/kg/min (5 mg/kg/min) if tolerated 4. The initial slow rate during the first 30 minutes allows you to monitor for hypersensitivity reactions before escalating.
For patients with cardiac dysfunction or fluid overload concerns, you can split the dose over 2 days (1 g/kg per day) rather than giving the full daily 0.4 g/kg dose 5. This is particularly relevant in GBS patients who may have autonomic instability.
Critical Pre-Treatment Considerations
Check serum IgA levels before administering IVIG 6. Patients with IgA deficiency risk severe anaphylaxis due to anti-IgA antibodies. If IgA deficiency is detected, use an IVIG preparation with reduced IgA content 6.
Monitor vital signs continuously throughout the infusion. If adverse reactions occur, slow or stop the infusion immediately. Once symptoms resolve, you may resume at a lower rate 4.
Clinical Context and Timing
Initiate IVIG as soon as possible after diagnosis—ideally within the first 2 weeks of symptom onset 7. The therapeutic benefit diminishes significantly when treatment is delayed beyond 2 weeks. Earlier treatment correlates with better disability scores, faster recovery, and shorter time to regain independent ambulation 7.
All grades of GBS warrant immediate workup and intervention given the potential for rapid progression to respiratory compromise 1, 2. Even grade 2 patients (moderate symptoms with some ADL interference) should have IVIG initiated promptly, with neurology consultation and close monitoring.
Monitoring During Treatment
- Admit patients to a unit with rapid ICU transfer capability for grades 3-4 (severe weakness, dysphagia, facial weakness, or respiratory involvement) 1, 2
- Perform frequent neurochecks and pulmonary function monitoring (negative inspiratory force and vital capacity) 1, 2
- Monitor for concurrent autonomic dysfunction, which can cause dangerous blood pressure fluctuations and arrhythmias 2
- Ensure adequate hydration before and during treatment to reduce thrombosis risk 4
Concurrent Steroid Therapy
While corticosteroids are not recommended for idiopathic GBS, in immune checkpoint inhibitor-related GBS, concurrent methylprednisolone 2-4 mg/kg/day is reasonable 1, 2. For severe cases (grades 3-4), pulse-dose methylprednisolone 1 g daily for 5 days may be added alongside IVIG 1.
What NOT to Do
Do not give a second course of IVIG or combine IVIG with plasma exchange in non-responders 3, 8. Multiple trials show no additional benefit from repeat IVIG or combination therapy, yet these practices persist in clinical practice 9. If patients fail to respond to the initial 5-day course, consider plasma exchange as an alternative rather than repeating IVIG 8.
Do not administer plasma exchange immediately after IVIG, as it will remove the immunoglobulin you just infused 1.
Pharmacokinetic Considerations
The increase in serum IgG levels (ΔIgG) after standard IVIG varies considerably between patients 10. Patients with more severe disease (higher GBS disability scores) and those receiving concurrent methylprednisolone have increased IgG clearance 11. A low ΔIgG at 2 weeks is independently associated with poor outcome 10, though the optimal strategy for these patients remains unclear.
Common Pitfalls
- Delaying treatment while awaiting confirmatory testing: Start IVIG based on clinical diagnosis; don't wait for nerve conduction studies or CSF results if GBS is strongly suspected
- Inadequate monitoring of respiratory function: Up to 22% of GBS patients require mechanical ventilation within the first week 3
- Failing to check IgA levels pre-treatment: This can result in life-threatening anaphylaxis
- Using medications that worsen myasthenia-like symptoms: Avoid β-blockers, IV magnesium, fluoroquinolones, aminoglycosides, and macrolides 2